Comparison of the safety and protective efficacy of vaccination with glycoprotein-G-deficient infectious laryngotracheitis virus delivered via eye-drop, drinking water or aerosol.
Infectious laryngotracheitis virus (ILTV), an alphaherpesvirus, causes respiratory disease in chickens and is commonly controlled by vaccination with conventionally attenuated virus strains. These vaccines have limitations due to residual pathogenicity and reversion to virulence. To avoid these problems and to better control disease, attention has recently turned towards developing a novel vaccine strain that lacks virulence gene(s). Glycoprotein G (gG) is a virulence factor in ILTV. A gG-deficient strain of ILTV has been shown to be less pathogenic than currently available vaccine strains following intratracheal inoculation of specific pathogen free chickens. Intratracheal inoculation of gG-deficient ILTV has also been shown to induce protection against disease following challenge with virulent virus. Intratracheal inoculation, however, is not suitable for large-scale vaccination of commercial poultry flocks. In this study, inoculation of gG-deficient ILTV via eye-drop, drinking water and aerosol were investigated. Aerosol inoculation resulted in undesirably low levels of safety and protective efficacy. Inoculation via eye-drop and drinking water was safe, and the levels of protective efficacy were comparable with intratracheal inoculation. Thus, gG-deficient ILTV appears to have potential for use in large-scale poultry vaccination programmes when administered via eye-drop or in drinking water.
Devlin
J M
JM
School of Veterinary Science, The University of Melbourne, Parkville, Victoria, Australia. devlinj@unimelb.edu.au
Browning
G F
GF
Gilkerson
J R
JR
Fenton
S P
SP
Hartley
C A
CA
D000336:Aerosols / Q000008:administration & dosage; D000818:Animals; D002645:Chickens / Q000276:immunology*; D004333:Drug Administration Routes; D006023:Glycoproteins / Q000172:deficiency* / Q000235:genetics; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D001352:Herpesvirus 1, Gallid / Q000235:genetics / Q000276:immunology*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination / Q000009:adverse effects / Q000379:methods*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000378:metabolism; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D014867:Water / Q000008:administration & dosage
D000336:Aerosols; D006023:Glycoproteins; D009883:Ophthalmic Solutions; D015164:Vaccines, Inactivated; D014764:Viral Proteins; D014765:Viral Vaccines; D014867:Water